Johnson & Johnson $JNJ Position Increased by Vident Advisory LLC

Vident Advisory LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,165 shares of the company’s stock after acquiring an additional 5,870 shares during the period. Vident Advisory LLC’s holdings in Johnson & Johnson were worth $24,573,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. The Manufacturers Life Insurance Company raised its holdings in Johnson & Johnson by 13.5% during the first quarter. The Manufacturers Life Insurance Company now owns 3,387,563 shares of the company’s stock valued at $561,793,000 after buying an additional 402,725 shares in the last quarter. Clough Capital Partners L P raised its holdings in Johnson & Johnson by 164.3% during the first quarter. Clough Capital Partners L P now owns 7,401 shares of the company’s stock valued at $1,227,000 after buying an additional 4,601 shares in the last quarter. WPG Advisers LLC bought a new position in Johnson & Johnson during the first quarter valued at about $518,000. Trexquant Investment LP bought a new position in Johnson & Johnson during the first quarter valued at about $15,964,000. Finally, Gerber Kawasaki Wealth & Investment Management raised its holdings in Johnson & Johnson by 9.1% during the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,364 shares of the company’s stock valued at $558,000 after buying an additional 282 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. Royal Bank Of Canada raised their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Stock Down 0.7%

JNJ stock opened at $175.50 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The company has a market cap of $422.67 billion, a PE ratio of 18.77, a price-to-earnings-growth ratio of 2.25 and a beta of 0.41. The business’s 50-day simple moving average is $165.45 and its 200 day simple moving average is $159.86. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the business earned $2.82 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.